SavaDx is a blood-based biomarker/diagnostic candidate to detect Alzheimer’s disease.

The underlying science for simufilam supports the development of a diagnostic technology to detect Alzheimer's disease with a simple blood test, called SavaDx.

SavaDx is an early-stage product candidate.

Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA without the use of antibodies.

SavaDx is a lower priority program compared to simufilam.